Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393341 · ClinicalTrials.gov registry record
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
A clinical trial of Breast Cancer Stage II and Breast Cancer Stage I, sponsored by Indiana University School of Medicine.
- Completed
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT00393341 is a study of Breast Cancer Stage II and Breast Cancer Stage I that has completed, run by Indiana University School of Medicine. The registered enrollment target is 68 participants, below the 179-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00393341, a study of Breast Cancer Stage II and Breast Cancer Stage I, has completed, sponsored by Indiana University School of Medicine.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose to quantitate endothelial progenitor cells (EPCs) in early and advanced breast cancer patients. Peripheral blood will be drawn from the eligible patients. Different type of EPCs will be isolated from the blood and quantitated.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (1)
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00393341
The ClinicalTrials.gov registry entry for NCT00393341 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (62% lower). The listed sponsor is Indiana University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT00393341 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00393341 about?
NCT00393341 is a clinical study titled "Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer". We propose to quantitate endothelial progenitor cells (EPCs) in early and advanced breast cancer patients. Peripheral blood will be drawn from the eligible patients. Different type of EPCs will be isolated from the blood and quantitated.
What is the current status of trial NCT00393341?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2006-10. Estimated completion is 2009-08.
What conditions does trial NCT00393341 study?
This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage I, Breast Cancer Stage IV.
What interventions are being tested in trial NCT00393341?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT00393341?
This trial is sponsored by Indiana University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00393341 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Stage II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
RECRUITING · Phase 2
-
Optimizing Surgical Decisions in Young Adults With Breast Cancer
RECRUITING · NA
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.